Click on the links or scroll down the page for information about work currently in progress by category. Please note that information summarised on this page is subject to change.
We produce prescribing guidance and other medicines resources to help patients and healthcare professionals in Wales make sure that medicines are used effectively and appropriately. When we produce these resources, we think it's important that people who might be affected by them have a chance to tell us their views. We ask patients and carers, patient organisations, prescribers and other healthcare professionals to comment on the resources we're developing. We'd like your views on the resources we're currently working on, listed below. You don't need to comment on the whole document; only on parts that seem relevant to you.
|
Title: Wales General Ophthalmic Services signed orders formulary Status: Consultation completed Remit: The aim of this document is to agree an approved list of eye preparations (medicines and devices) for inclusion on the WGOS signed orders formulary. Estimated publication date: December 2025 - February 2026 |
|
Title: All Wales self-administration of medicines framework Status: Consultation completed Remit: The self-administration of medicines framework aims to ensure that patients who self-administer their medicines at home can do so safely during hospital admissions. Estimated publication date: December 2025 - February 2026 |
|
Title: All Wales HIV-1 antiretroviral prescribing guidelines Status: Consultation completed Remit: The All Wales HIV-1 antiretroviral prescribing guidelines aim to support clinicians and other healthcare professionals in the pharmacological management of HIV-1 to deliver good prescribing practice, optimise treatment to suppress the viral load while minimising the risk of adverse effects, and improve the person’s health-related quality of life. Estimated publication date: March–May 2026 |
|
Title: History-based penicillin allergy de-labelling Status: Consultation completed Remit: The History-based penicillin allergy de-labelling guideline aims to support healthcare professionals to review patients with a penicillin allergy label appropriately and ensure a consistent all Wales approach. This guidance is relevant to all registered healthcare professionals and is for reviewing people, in primary care and other settings, with very low risk of true penicillin allergy and who do not require oral challenge for de-labelling. Estimated publication date: March–May 2026 |
|
Title: All Wales guidance for medicines training and education - for support workers in health and social care Status: Consultation completed Remit: This guidance has been developed through collaboration with partners in both health and social care and aims to provide a framework for planning and delivering training and education to ensure people are supported to take their medicines safely and effectively. Estimated publication date: March–May 2026 |
|
Title: All Wales gabapentinoid resources for chronic pain Status: Consultation open Remit: The All Wales gabapentinoid resources for chronic pain have been developed to support healthcare professionals in the appropriate prescribing, review, and deprescribing of gabapentin and pregabalin (gabapentinoids) for chronic pain. The resources are split into four packs and provide practical guidance to support shared decision-making with patients, promote a holistic approach to chronic pain management, and reduce inappropriate prescribing. Each resource pack can be used on its own or alongside the others to support discussions with patients. Estimated publication date: March–May 2026 |
|
Title: All Wales Pre-Prescribing Policy for Final Year Medical Students, Foundation Trainee Pharmacists and Non Medical Prescribing Trainees Status: Consultation open Remit: The All Wales Pre-Prescribing Policy for Final Year Medical Students, Foundation Trainee Pharmacists and Non‑Medical Prescribing Trainees aims to establish a standardised approach to pre-prescribing across clinical placements in Wales. Estimated publication date: June–August 2026 |
|
Medicine name: gilteritinib (Gilteritinib Astellas®) Reference number: 3663 Indication: Maintenance treatment of acute myeloid leukaemia (AML) in patients with FLT3 mutation and evidence of minimum residual disease, before or after haematopoietic stem cell transplant Licence status: Off-label for this indication AWMSG Scrutiny Panel meeting date: 05/02/2026 |
Patients, carers and patient organisations - please see our New medicines needing your views page for answers to some questions you might have about making a submission.
Clinical experts - please see our Clinical expert opinion for medicine appraisals page for background information.
We'd like to receive your submission before the stated deadline (so we can prepare the meeting papers). But we'll still try to include any that arrive late.
|
Medicine name: emicizumab (Hemlibra®) Reference number: 4742 Indication: Routine prophylaxis of bleeding episodes in patients with haemophilia A without factor VIII inhibitors who have moderate disease (FVIII = 1% and = 5%) with severe bleeding phenotype Patient and carer submission: Download form or submit online Patient organisation submission: Download form or submit online Clinical experts submission: Download form LOWMAG meeting date: 15/04/2026 AWMSG meeting date: 20/05/2026 Patient organisation/patient and carer/clinician submission deadline: 09/03/2026 |
|
Medicine name: progesterone (Prometrium®) Reference number: 6820 Indication: For the prevention of miscarriage in women presenting with bleeding in the first trimester of pregnancy and have a history of recurrent miscarriages. Patient and carer submission: Download form or submit online Patient organisation submission: Download form or submit online Clinical experts submission: Download form LOWMAG meeting date: 15/04/2026 AWMSG meeting date: 20/05/2026 Patient organisation/patient and carer/clinician submission deadline: 09/03/2026 |
|
Medicine name: budesonide (Jorveza®) Reference number: 4507 Indication: As maintenance therapy for eosinophilic esophagitis in adults (older than 18 years of age) Patient and carer submission: Download form or submit online Patient organisation submission: Download form or submit online Clinical experts submission: Download form LOWMAG meeting date: 15/04/2026 AWMSG meeting date: 20/05/2026 Patient organisation/patient and carer/clinician submission deadline: 09/03/2026 |
|
Medicine name: nivolumab (Opdivo®) + ipilimumab (Yervoy®) Reference number: OW35 Indication: Neoadjuvant treatment for patients with resectable macroscopic stage III melanoma with ≥1 pathologically proven lymph node metastasis and up to 3 in-transit metastases Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk Submission deadline: 01/01/2026 OWMAG date: 09/02/2026 AWMSG date: 11/03/2026 |
|
Title: AWMSG annual report 2025-2026 Summary: Review of the activities and achievements of the All Wales Medicine Strategy Group (AWMSG) between April 2025 and March 2026. Estimated publication date: September 2026 |
|
Title: IPFR annual report 2025-2026 Summary: Review of Individual Patient Funding Request activity in Wales between April 2025 and March 2026. Estimated publication date: November 2026 |